LOXL2 and lung carcinoma: Peng et al. used the LOXL2 inhibitor ellagic acid (a dimeric derivative of gallic acid) combined with anti-PD-1 therapy to significantly inhibit the growth and metastasis of lung cancer and increase the CD8 T-cell infiltration in tumor tissue [78].